Cardiol Therapeutics Inc Class A - Asset Resilience Ratio

Latest as of December 2025: 90.67%

Cardiol Therapeutics Inc Class A (CRDL) has an Asset Resilience Ratio of 90.67% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Cardiol Therapeutics Inc Class A current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CA$21.42 Million

≈ $15.49 Million USD Cash + Short-term Investments

Total Assets

CA$23.62 Million

≈ $17.09 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Cardiol Therapeutics Inc Class A's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Cardiol Therapeutics Inc Class A balance sheet assets.

Liquid Assets Composition Over Time

This chart breaks down Cardiol Therapeutics Inc Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Cardiol Therapeutics Inc Class A balance sheet liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CA$21.42 Million	90.67%
Short-term Investments	CA$0.00	0%
Total Liquid Assets	CA$21.42 Million	90.67%

Asset Resilience Insights

Very High Liquidity: Cardiol Therapeutics Inc Class A maintains exceptional liquid asset reserves at 90.67% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Cardiol Therapeutics Inc Class A Industry Peers by Asset Resilience Ratio

Compare Cardiol Therapeutics Inc Class A's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt F:RIG2	Drug Manufacturers - Specialty & Generic	0.20%
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Beijing Tongrentang Co Ltd SHG:600085	Drug Manufacturers - Specialty & Generic	0.50%
Takeda Pharmaceutical Company Limited F:TKDA	Drug Manufacturers - Specialty & Generic	0.69%
Changchun High & New Technology Industries Group Inc SHE:000661	Drug Manufacturers - Specialty & Generic	5.50%
Neuland Laboratories Limited NSE:NEULANDLAB	Drug Manufacturers - Specialty & Generic	9.65%
China Resources Double-Crane Pharmaceutical Co Ltd SHG:600062	Drug Manufacturers - Specialty & Generic	1.18%
Zhejiang Hisun Pharmaceutical Co Ltd SHG:600267	Drug Manufacturers - Specialty & Generic	0.01%

Annual Asset Resilience Ratio for Cardiol Therapeutics Inc Class A (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Cardiol Therapeutics Inc Class A.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	90.67%	CA$21.42 Million ≈ $15.49 Million	CA$23.62 Million ≈ $17.09 Million	-5.30pp
2024-12-31	95.97%	CA$30.58 Million ≈ $22.12 Million	CA$31.86 Million ≈ $23.05 Million	+0.62pp
2023-12-31	95.35%	CA$34.99 Million ≈ $25.31 Million	CA$36.70 Million ≈ $26.55 Million	-0.63pp
2022-12-31	95.97%	CA$59.53 Million ≈ $43.06 Million	CA$62.03 Million ≈ $44.87 Million	+0.43pp
2021-12-31	95.54%	CA$83.96 Million ≈ $60.74 Million	CA$87.88 Million ≈ $63.57 Million	+6.91pp
2020-12-31	88.63%	CA$14.09 Million ≈ $10.19 Million	CA$15.89 Million ≈ $11.50 Million	+43.37pp
2019-12-31	45.27%	CA$7.02 Million ≈ $5.08 Million	CA$15.50 Million ≈ $11.21 Million	-22.52pp
2018-12-31	67.78%	CA$16.73 Million ≈ $12.10 Million	CA$24.68 Million ≈ $17.86 Million	-5.39pp
2017-12-31	73.17%	CA$2.36 Million ≈ $1.70 Million	CA$3.22 Million ≈ $2.33 Million	--

pp = percentage points

About Cardiol Therapeutics Inc Class A

TO:CRDL Canada Drug Manufacturers - Specialty & Generic

Market Cap

$208.43 Million

CA$288.13 Million CAD

Market Cap Rank

#16606 Global

#509 in Canada

Share Price

CA$2.58

Change (1 day)

-6.86%

52-Week Range

CA$1.28 - CA$3.16

All Time High

CA$8.13